Buyers Win Class Cert. In Blood Clot Drug Monopoly Suit

Law360 (September 20, 2019, 6:56 PM EDT) -- A Tennessee federal judge on Friday certified a class of thousands of Lovenox buyers in a suit from a Nashville hospital and a union health plan accusing Momenta and Sandoz of conspiring to monopolize the blood clot drug and its generic version.

U.S. District Judge Waverly D. Crenshaw Jr. accepted a tweaked class definition proposed by Nashville General Hospital and the American Federation of State, County and Municipal Employees District Council 37 Health & Security Plan.

The class will include thousands of hospitals, uninsured people and third-party buyers that indirectly bought brand-name Lovenox or generic enoxaparin in 29 states and Washington,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS